Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway
- 28 February 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (5), 1951-1959
- https://doi.org/10.1158/0008-5472.can-09-3201
Abstract
Understanding the molecular basis and target of traditional medicine is critical for drug development. Celastrol, derived from Trypterygium wilfordii Hook F. (“Thunder of God Vine”), a traditional Chinese medicine plant, has been assigned anticancer activities, but its mechanism is not well understood. Here, we investigated whether Celastrol could inhibit angiogenesis-mediated tumor growth and, if so, through what mechanism. When given s.c. to mice bearing human prostate cancer (PC-3 cell) xenografts, Celastrol (2 mg/kg/d) significantly reduced the volume and the weight of solid tumors and decreased tumor angiogenesis. We found that this agent inhibited vascular endothelial growth factor (VEGF)–induced proliferation, migration, invasion, and capillary-like structure formation by primary cultured human umbilical vascular endothelial cells (HUVEC) in a dose-dependent manner. Furthermore, Celastrol abrogated VEGF-induced sprouting of the vessels from aortic rings and inhibited vascular formation in the Matrigel plug assay in vivo. To understand the molecular mechanism of these activities, we next examined the signaling pathways in treated HUVECs and PC-3 tumor cells. Celastrol suppressed the VEGF-induced activation of AKT, mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase (P70S6K). Additionally, we found that Celastrol inhibited the proliferation of prostate cancer cells and induced apoptosis, and these effects correlated with the extent of inhibition of AKT/mTOR/P70S6K signaling. Taken together, our results suggest that Celastrol targets the AKT/mTOR/P70S6K pathway, which leads to suppression of tumor growth and angiogenesis. Cancer Res; 70(5); 1951–9Keywords
This publication has 36 references indexed in Scilit:
- Inhibition of NF-κB activation through targeting IκB kinase by celastrol, a quinone methide triterpenoidBiochemical Pharmacology, 2006
- Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulatorsCancer Cell, 2006
- Tripterine inhibits the expression of adhesion molecules in activated endothelial cellsJournal of Leukocyte Biology, 2006
- Celastrol, a Triterpene Extracted from the Chinese “Thunder of God Vine,” Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer Growth in Nude MiceCancer Research, 2006
- Chronic Inhibition of Cardiac Kir2.1 and hERG Potassium Channels by Celastrol with Dual Effects on Both Ion Conductivity and Protein TraffickingPublished by Elsevier BV ,2006
- Vascular Endothelial Growth Factor Contributes to Prostate Cancer–Mediated Osteoblastic ActivityCancer Research, 2005
- The Akt-mTOR tango and its relevance to cancerCancer Cell, 2005
- Celastrol Blocks Neuronal Cell Death and Extends Life in Transgenic Mouse Model of Amyotrophic Lateral SclerosisNeurodegenerative Diseases, 2005
- Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's diseaseProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2001
- A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis.2001